Xeljanz.com

Ping response time 13ms Good ping
Health Website
Domain provide by comlaude.com. Domain ID : 1546347256_DOMAIN_COM-VRSN
Created : 2009-03-10T13:08:20Z. Expired: 2026-03-10T13:08:20Z (0 Years, 323 Days left)
Host name 104.18.35.11, IP address: 104.18.35.11, location: United States
. Category rank: 781

System updated on 2025/04/21

Category
Health	42%
Pharmacy	33%
Health Conditions and Concerns	17%
Others	8%

Keyword Suggestion

Xeljanz

Xeljanz copay card

Xeljanz xr

Xeljanz side effects

Xeljanz medication

Xeljanz drug

Xeljanz cost

Xeljanz generic

Xeljanz package insert

Xeljanz drug class

Xeljanz 5 mg

Xeljanz patient assistance forms

Xeljanz dosage

Xeljanz moa

Xeljanz dosing

Xeljanz patient portal

Xeljanz rheumatoid arthritis

Xeljanz 11 mg

Xeljanz patient assistance

Xeljanz mechanism of action

Xeljanz copay assistance program

Xeljanz spc

Xeljanz.com lookup results from whois.comlaude.com server:

Network

Owner

Technical support

Abuse

Domain Provider	Number Of Domains
godaddy.com	286730
namecheap.com	101387
networksolutions.com	69118
tucows.com	52617
publicdomainregistry.com	39120
whois.godaddy.com	32793
enomdomains.com	23825
namesilo.com	21429
domains.google.com	21384
cloudflare.com	20573
gmo.jp	18110
name.com	17601
fastdomain.com	14708
register.com	13495
net.cn	12481
ionos.com	12416
ovh.com	12416
gandi.net	12305
registrar.amazon.com	12111

Host Informations

Check all domain's dns records

See Web Sites Hosted on 104.18.35.11

Fetching Web Sites Hosted

Site Inspections

Loading ...

Port Scanner (IP: 104.18.35.11)

› Ftp: 21

› Ssh: 22

› Telnet: 23

› Smtp: 25

› Dns: 53

› Http: 80

› Pop3: 110

› Portmapper, rpcbind: 111

› Microsoft RPC services: 135

› Netbios: 139

› Imap: 143

› Ldap: 389

› Https: 443

› SMB directly over IP: 445

› Msa-outlook: 587

› IIS, NFS, or listener RFS remote_file_sharing: 1025

› Lotus notes: 1352

› Sql server: 1433

› Point-to-point tunnelling protocol: 1723

› My sql: 3306

› Remote desktop: 3389

› Session Initiation Protocol (SIP): 5060

› Virtual Network Computer display: 5900

› X Window server: 6001

› Webcache: 8080

Spam Check (IP: 104.18.35.11)

› Dnsbl-1.uceprotect.net:

› Dnsbl-2.uceprotect.net:

› Dnsbl-3.uceprotect.net:

› Dnsbl.dronebl.org:

› Dnsbl.sorbs.net:

› Spam.dnsbl.sorbs.net:

› Bl.spamcop.net:

› Recent.dnsbl.sorbs.net:

› All.spamrats.com:

› B.barracudacentral.org:

› Bl.blocklist.de:

› Bl.emailbasura.org:

› Bl.mailspike.org:

› Bl.spamcop.net:

› Cblplus.anti-spam.org.cn:

› Dnsbl.anticaptcha.net:

› Ip.v4bl.org:

› Fnrbl.fast.net:

› Dnsrbl.swinog.ch:

› Mail-abuse.blacklist.jippg.org:

› Singlebl.spamgrouper.com:

› Spam.abuse.ch:

› Spamsources.fabel.dk:

› Virbl.dnsbl.bit.nl:

› Cbl.abuseat.org:

› Dnsbl.justspam.org:

› Zen.spamhaus.org:

Email address with xeljanz.com

Found 0 emails of this domain

Similar sites

List of our tools

Emails by domain

Mobile Friendly Check

Page Speed Check

DNS Lookup

Ports Scan

Sites on host

Sitemap Generator

Websites Listing

We found Websites Listing below when search with xeljanz.com on Search Engine

Contact Us - XELJANZ

Contact Us. If you have questions, concerns, or comments, please call our XELJANZ Information Center toll-free at 1-844-935-5269 Monday through Friday, 8:00 AM–8:00 PM ET. You are encouraged to report adverse events related to Pfizer products by calling 1 …

Xeljanz.com

Xeljanz – Consumer Justice Action

Xeljanz XR® or any government agency. www.consumerjusticeaction.com is the property of Shield Legal LP. 10525 Vista Sorrento Pwk, Suite 220, San Diego CA 92121 This website is not part of the Facebook website or Facebook, Inc. Additionally, this site is NOT endorsed by Facebook in any way.

Consumerjusticeaction.com

XELJANZ / XELJANZ XR (tofacitinib) - Pfizer Canada

2021-02-24 · XELJANZ / XELJANZ XR (tofacitinib) | Pfizer Canada. test. Learn more about how we innovate to bring therapies to patients that significantly improve their lives. About Us. Research. Research and development are at the heart of fulfilling Pfizer's purpose as we work to translate advanced science and technologies into the therapies that matter most.

Pfizer.ca

Welcome to XELJANZ.ca | XELJANZ

Bienvenue sur le site XELJANZ.ca. Pour obtenir de plus amples renseignements concernant le programme de soutien. ou vous y inscrire, composez le 1-855-935-3539, du lundi au vendredi, entre 8 h et. 20 h, HE, ou envoyez-nous un courriel à [email protected]. Landing Footer.

Xeljanz.ca

XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse ...

2022-01-12 · Use XELJANZ/XELJANZ XR with caution in older patients, especially geriatric patients (above 65 years of age), patients who are current or past smokers, and patients with other CV or malignancy risk factors. Use XELJANZ at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response in patients with ulcerative …

Recalls-rappels.canada.ca

Xeljanz®/Xeljanz® XR/Xeljanz® Oral Solution (tofacitinib ...

Xeljanz or Xeljanz Oral Solution will be approved based on all of the following criteria: (1) Diagnosis of active polyarticular juvenile idiopathic arthritis -AND- (2) Patient is not receiving Xeljanz or Xeljanz Oral Solution in combination with any of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)] …

Uhcprovider.com

FDA Issues Update to XELJANZ® Prescribing Information in ...

Avoid XELJANZ/XELJANZ XR/XELJANZ Oral Solution in patients at risk. Discontinue XELJANZ/XELJANZ XR/XELJANZ Oral Solution and promptly evaluate patients with symptoms of thrombosis. A XELJANZ 10 mg twice daily (or XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA. In a long-term extension study in UC, five ...

Pfizer.com

HIGHLIGHTS OF PRESCRIBING INFORMATION : XELJANZ/XELJANZ ...

XELJANZ/XELJANZ Oral Solution 5 mg twice daily or weight-based equivalent twice daily. (2.4) Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing Dosage Adjustment See the full prescribing information for dosage adjustments by indication for patients receiving CYP2C19 and/or CYP3A4 …

Accessdata.fda.gov

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …

XELJANZ induction therapy should be discontinued in patients who show no evidence of adequate therapeutic benefit by Week 16. In patients who have responded to treatment with XELJANZ, corticosteroids may be cautiously reduced and/or discontinued in accordance with standard of care. Dose Interruption or Discontinuation due to Serious Infections and …

Pdf.hres.ca

Xeljanz® - Pfizer.de

XELJANZ ist ein Arzneimittel, das den Wirkstoff Tofacitinib enthält. XELJANZ wird für die Behandlung der folgenden Entzündungskrankheiten angewendet: Rheumatoide Arthritis. Psoriasis-Arthritis. Colitis ulcerosa. Ankylosierende Spondylitis. Polyartikuläre juvenile idiopathische Arthritis und juvenile Psoriasis-Arthritis.

Pfizer.de

FDA requires warnings about increased risk of serious ...

2021-12-07 · Xeljanz/Xeljanz XR, Olumiant, and Rinvoq are used to treat certain serious, chronic, and progressive inflammatory conditions. Xeljanz was the first to be approved in 2012.

Fda.gov

XELJANZ / XELJANZ XR (tofacitinib) The Product Monograph ...

XELJANZ / XELJANZ XR (tofacitinib) The Product Monograph is unavailable. Medical Information . In order to provide you with relevant and meaningful content we need to know more about you. Please choose the category that best describes you. This content is intended for Canadian Healthcare Professionals. Would you like to proceed? For Canadian Healthcare …

Pfizermedicalinformation.ca

XELJANZ / XELJANZ XR (tofacitinib) | Information Médicale ...

XELJANZ medication page for healthcare professionals to search for scientific information on Pfizer medications. Also find the prescibing information, announcements, resources, and channels to connect with Pfizer Medical Information.

Pfizermedicalinformation.ca

Xeljanz oral: Uses, Side Effects, Interactions, Pictures ...

Xeljanz. - Uses, Side Effects, and More. Warnings: Tofacitinib may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any ...

Webmd.com

XELJANZ - PLM

XELJANZ® 10 mg dos veces al día, inhibió el progreso del daño estructural en comparación con placebo más MTX a los 6 y 12 meses. Cuando se administra a dosis de 5 mg dos veces al día, XELJANZ® presenta efectos similares sobre el progreso medio del daño estructural a los 6 y 12 meses (estadísticamente no significativo).

Medicamentosplm.com

UpToDate

Uptodate.com

Domains Expiration Date Updated

Site	Provider	Expiration Date
mccookefree.org	whois.wildwestdomains.com	-3 Years, -11 Days
dfakto.com	ovh.com	-2 Years, -136 Days
iwcoffice.org	namebright.com	-2 Years, -78 Days
nasljedje.org	enom.com	-2 Years, -261 Days
independentcan.com	networksolutions.com	297 Days
risem.net	gmo.jp	5 Years, 356 Days
newsingermany.com	mainreg.com	-2 Years, -74 Days
oque-e.com	name.com	-1 Years, -305 Days
pitpedia.com	godaddy.com	-1 Years, -339 Days
visitlaramie.org	whois.godaddy.com	-1 Years, -246 Days